Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective

Infectious Diseases and Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: March 18, 2025

Immunocompromised patients are disproportionately impacted by severe disease, hospitalization, and mortality associated with coronavirus disease 2019 (COVID-19). To optimize the management of these in clinical practice, we convened an expert panel to review current evidence on acute respiratory syndrome 2 (SARS-CoV-2) vaccine responses COVID-19 immunocompromised populations. We identified four main groups—solid organ transplant recipients, receiving allogeneic hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T therapy, treated for hematologic malignancies, inflammatory diseases—who mount suboptimal humoral SARS-CoV-2 vaccination at increased risk COVID-19-related outcomes. A wide range factors were reduced and/or poor outcomes, most commonly older age, comorbidities, type number immunosuppressive therapies. believe that early identification close monitoring at-risk patients, plus regular booster vaccinations, prophylactic monoclonal antibody non-pharmacologic prevention measures, prompt antiviral treatment, other mitigation strategies, critical protect against infection COVID-19. Although people will fully recover from COVID-19, who less able fight more likely be hospitalized die improve treatment people, 10 experts France met discuss latest medical research this area. The focused groups people: (1) transplants; (2) transplants therapy; (3) being blood cancers; (4) diseases (such as rheumatoid arthritis). These protected after develop forms pre-existing conditions diabetes, obesity, heart, lung, kidney disease), immunosuppressants. agreed it is important quickly identify clinic, so they can receive vaccines every 6 months. For unable build up their immunity vaccination, treatments also used prevent infection. In recommend using therapies nirmatrelvir/ritonavir remdesivir) becoming severe. addition measures mask wearing social distancing), strategies help

Language: Английский

---

COVID‐19 in cancer patients: The impact of vaccination on outcomes early in the pandemic

Cancer Medicine, Journal Year: 2023, Volume and Issue: 12(24), P. 22006 - 22022

Published: Dec. 1, 2023

Abstract Background With the rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic, development effective and safe vaccines was utmost importance to protect vulnerable individuals, including cancer patients. Studies comparing clinical outcomes patients with or without vaccination against disease 2019 (COVID‐19) have not demonstrated clear benefit. We aimed determine protective effects COVID‐19 by vaccinated unvaccinated after initial phase vaccine roll‐out identify risk factors associated hospitalization, COVID‐19, 30‐day attributable mortality. Methods performed a retrospective cohort study diagnosed polymerase chain reaction on nasal swabs between January 1, 2021 July 30, 2021. Outcomes interest included Univariate multivariate analyses were outcomes, using status as variable in all models. Results Key factors, such age ≥ 60 years; comorbidities diabetes mellitus, heart failure, lung diseases; specific types (leukemia lymphoma) independently hospital admission for mortality regardless their status. Vaccinated protected but no impact hospitalization due COVID‐19. Conclusion Our highlights significant benefit patients—specifically its protection

Language: Английский

---

Real-World Data on Neutralizing Antibody and Safety of COVID-19 Vaccine against SAR-CoV2 Wild Type and Omicron Variant in Solid Cancer Patients

Published: May 13, 2024

Cancer patients, susceptible to severe COVID-19 outcomes, exhibit varied vaccine responses, particularly those who are receiving chemotherapy. This prospective cohort study enrolled 115 cancer and data from 91 patients received two doses of vaccines were analyzed. Blood was drawn at baseline, day 28, 6 months post-second dose for neutralizing antibody analysis. The primary outcome seroconversion rate against wild type Omicron 28. Secondary outcomes included months, factors associated with seroconversion, safety. Of the 157 screened, enrolled, 45% Seroconversion rates 28 77% 62% Omicron. Chemotherapy did not affect (p=0.789 type, p=0.597 Omicron). Vaccine positively correlated an adjusted ORR 25.86 (p=0.029) 17.38 (p

Language: Английский

---

The signature of SARS-CoV-2-related genes predicts the immune therapeutic response and prognosis in breast cancer

BMC Medical Genomics, Journal Year: 2024, Volume and Issue: 17(1)

Published: Oct. 31, 2024

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an exceptionally contagious single-stranded RNA virus with a strong positive contagion. The COVID-19 pandemic refers to the swift worldwide dissemination of SARS-CoV-2 infection, which began in late 2019. epidemic has disrupted many cancer treatments. A few reports indicate that prevalence treatment breast patients (BCs). However, role occurrence and prognosis BC not been elucidated. Here, we applied bioinformatics construct prognostic signature SARS-CoV-2-related genes (SCRGs). Specifically, weighted gene co-expression network analysis (WGCNA) was utilized extract co-expressed differentially expressed (DEGs) SCRGs. Then, least absolute shrinkage selection operator (LASSO) algorithm univariate regression screen out three hub (DCTPP1, CLIP4 ANO6) constructed risk score model. We further analyzed tumor immune invasion, HLA-related genes, checkpoint inhibitors (ICIs), sensitivity anticancer drugs different related subgroups. In addition, have developed nomination map expand clinical applicability. results our study BCs high-risk are linked negative outcomes, lower scores, reduced responsiveness medications. This suggests could be used guide assessment decisions for BCs.

Language: Английский

---

Neutralizing antibodies and safety of a COVID-19 vaccine against SARS-CoV-2 wild-type and Omicron variants in solid cancer patients

PLoS ONE, Journal Year: 2024, Volume and Issue: 19(11), P. e0310781 - e0310781

Published: Nov. 7, 2024

The aim of this study was to assess the seroconversion rate and percent inhibition neutralizing antibodies against wild-type Omicron variants SARS-CoV-2 in patients with solid cancer who received two COVID-19 vaccine doses by comparing chemotherapy nonchemotherapy groups.

Language: Английский

---